Physician profile
Surendra Bagaria
NPI 1346232105
$3,447.18
in general payments reported to CMS, 2019-2025
26 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $236 · 2021: $479 · 2022: $545 · 2023: $288 · 2024: $854 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $474.36 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $424.75 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $309.11 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $281.94 | 2024-2025 | Optimizer |
| Janssen Pharmaceuticals, INC | $248.90 | 2019-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $220.72 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $198.99 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $168.70 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $167.14 | 2021-2023 | Watchman Flx |
| Atricure, INC. | $142.12 | 2024 | |
| W. L. Gore & Associates, INC. | $118.78 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $110.17 | 2019-2024 | Livalo |
| Pfizer INC. | $79.72 | 2019-2020 | |
| Novo Nordisk INC | $75.13 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.54 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.74 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $55.73 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $42.58 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.26 | 2019 | |
| Amarin Pharma, INC. | $41.15 | 2019 | |
| Akcea Therapeutics, INC. | $38.14 | 2019 | |
| Edwards Lifesciences Corporation | $21.18 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $20.21 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.86 | 2020 | |
| Scpharmaceuticals INC. | $15.52 | 2025 | |
| Abbott Laboratories | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Bagaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.